Follicular Lymphoma Clinical Trials

147 recruitingLast updated: June 17, 2026

There are 147 actively recruiting follicular lymphoma clinical trials across 51 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include New York, New York, United States, Houston, Texas, United States, Madrid, Spain. Updated daily from ClinicalTrials.gov.


Follicular Lymphoma Trials at a Glance

147 actively recruiting trials for follicular lymphoma are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 2 with 68 trials, with the heaviest enrollment activity in New York, Houston, and Madrid. Lead sponsors running follicular lymphoma studies include University of Washington, Fondazione Italiana Linfomi - ETS, and City of Hope Medical Center.

Browse follicular lymphoma trials by phase

Treatments under study

About Follicular Lymphoma Clinical Trials

Looking for clinical trials for Follicular Lymphoma? There are currently 85 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Follicular Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Follicular Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 147 trials

Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+1 more
University of California, Davis34 enrolled1 locationNCT06854159
Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)
Tempus AI550 enrolled6 locationsNCT07154823
Recruiting
Phase 3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled267 locationsNCT06337318
Recruiting
Phase 1

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeOne Medicines780 enrolled277 locationsNCT05100862
Recruiting
Phase 1

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 2

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma

Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China80 enrolled2 locationsNCT07555470
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting

Clonal Evolution in Follicular Lymphoma

Follicular Lymphoma
National Cancer Institute (NCI)200 enrolled1 locationNCT03190928
Recruiting
Phase 3

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Follicular Lymphoma
The Lymphoma Academic Research Organisation790 enrolled116 locationsNCT06284122
Recruiting
Phase 1

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Follicular LymphomaLymphoma Diffuse Large B-cellLymphoma, Non-Hodgkin's
Eli Lilly and Company460 enrolled46 locationsNCT07226843
Recruiting
Phase 1Phase 2

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 2

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Recurrent Follicular LymphomaRefractory Follicular LymphomaGrade 1 Follicular Lymphoma+2 more
University of Washington22 enrolled1 locationNCT06948786
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma ( FL)
Genmab1,095 enrolled266 locationsNCT06191744
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 3

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Follicular Lymphoma
Fondazione Italiana Linfomi - ETS190 enrolled49 locationsNCT05929222
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633